Credit: NIAID A Phase 2/3 trial to evaluate a new fully-human polyclonal antibody therapeutic targeted to SARS-CoV-2, called SAB-185, has begun enrolling non-hospitalized people with mild...
Swiss drugmaker Roche predicted on April 21 that demand for the company's drugs would accelerate for the remainder of 2021, after first-quarter sales of Covid-19 tests...
It's normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won't tell you which you are.
It's normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won't tell you which you are.
The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which The post EMA starts review of GSK/Vir COVID-19...
UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last The post Clive Dix: Rebuilding UK biotech appeared...
Dominant G-form Spike protein ‘puts its head up’ more frequently to latch on to receptors, but that makes it more vulnerable to neutralization Credit: Los Alamos...
Shares of Inovio climbed in trading after the company announced its DNA vaccine candidate for Covid-19 induced a robust T-cell response against multiple variants of the...
Is more testing really the best way to achieve our aim of living safely with COVID-19?
Variants of the original SARS-CoV-2 are now in wide circulation. That means the third wave of COVID-19 has come with new questions about the variants, their...